Abstract | BACKGROUND: METHODS: RESULTS:
Transplantation was performed in 57 patients as of March 2014. Survival rate was 86.7% at 1 year, 82.5% at 3 years, 73.7% at 5 years, and 73.7% at 10 years. Of the 98 patients, 21 had an inactive status and received sirolimus more frequently than those with an active history (67% vs. 5%, p<0.001). Nine of twelve patients who remained inactive as of March 2014 initiated sirolimus before or while on a waiting list, and remained on sirolimus thereafter. Although the statistical analysis showed no statistically significant difference, the survival rate after registration tended to be better for lung transplant recipients than for those who awaited transplantation (p = 0.053). CONCLUSIONS:
|
Authors | Katsutoshi Ando, Yoshinori Okada, Miki Akiba, Takashi Kondo, Tomohiro Kawamura, Meinoshin Okumura, Fengshi Chen, Hiroshi Date, Takeshi Shiraishi, Akinori Iwasaki, Naoya Yamasaki, Takeshi Nagayasu, Masayuki Chida, Yoshikazu Inoue, Toyohiro Hirai, Kuniaki Seyama, Michiaki Mishima, Respiratory Failure Research Group of the Japanese Ministry of Health, Labour, and Welfare |
Journal | PloS one
(PLoS One)
Vol. 11
Issue 1
Pg. e0146749
( 2016)
ISSN: 1932-6203 [Electronic] United States |
PMID | 26771878
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- Sirolimus
|
Topics |
- Adult
- Anti-Bacterial Agents
(administration & dosage, therapeutic use)
- Female
- Humans
- Japan
- Lung Neoplasms
(surgery)
- Lung Transplantation
- Lymphangioleiomyomatosis
(surgery)
- Male
- Middle Aged
- Retrospective Studies
- Sirolimus
(administration & dosage, therapeutic use)
- Survival Rate
- Young Adult
|